An updated patent review of autotaxin inhibitors (2017–present)

References

• Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002;277(42):39436–39442.
   PubMed Web of Science ®Google Scholar
• Aikawa S, Hashimoto T, Kano K, et al. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015;157(2):81–89.
   PubMed Web of Science ®Google Scholar
• Nam SW, Clair T, Campo CK, et al. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000;19(2):241–247.
   PubMed Web of Science ®Google Scholar
• Gotoh M, Fujiwara Y, Yue J. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans. 2012;40(1):31–36.
   PubMedGoogle Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45–54.
   PubMed Web of Science ®Google Scholar
• Contos JJA, Fukushima N, Weiner JA, et al. Requirement for the LPA 1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA. 2000;97(24):13384–13389.
   PubMed Web of Science ®Google Scholar
• Kremer AE, Martens JJWW, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008–1018.
   PubMed Web of Science ®Google Scholar
• Thirunavukkarasu K, Tan B, Swearingen CA, et al. Pharmacological characterization of a potent inhibitor of autotaxin in animal models of inflammatory bowel disease and multiple sclerosis. J Pharmacol Exp Ther. 2016;359(1):207–214.
   PubMed Web of Science ®Google Scholar
• Sevastou I, Kaffe E, Mouratis MA, et al. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA2/ LPC and ATX/ LPA axes. Biochim Biophys Acta, Mol Cell Biol Lipids. 2013;1831(1):42–60.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Natarajan V. Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling. Biochim Biophys Acta Mol Cell Biol Lipids. 2013;1831(1):86‐92.
   Web of Science ®Google Scholar
• Bourgion SG, Zhao C. Autotaxin and lysophospholipids in rheumatoid arthritis. Curr Opin Invest Drugs. 2010;11:515‐526.
   Google Scholar
• Dsouza K, Paramel GV, Kienesberger PC. Lysophosphatidic acid signaling in obesity and insulin resistance. Nutrients. 2018;10:1‐20.
   Web of Science ®Google Scholar
• Parrill AL, Baker DL. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts. Expert Opin Ther Pat. 2010;20(12):1619–1625.
   PubMed Web of Science ®Google Scholar
• Barbayianni E, Magrioti V, Moutevelis-Minakakis P, et al. Autotaxin inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(9):1123–1132.
   PubMed Web of Science ®Google Scholar
• Nikolaou A, Kokotou MG, Limnios D, et al. Autotaxin inhibitors: a patent review (2012-2016). Expert Opin Ther Pat. 2017;27(7):815–829.
   PubMed Web of Science ®Google Scholar
• Hausmann J, Kamtekar S, Christodoulou E, et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol. 2011;18(2):198–204.
   PubMed Web of Science ®Google Scholar
• Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci. 2005;30(10):542–550.
   PubMed Web of Science ®Google Scholar
• Houben AJ, van Wijk XM, van Meeteren LA, et al. The polybasic insertion in autotaxin alpha confers specific binding to heparin and cell surface heparan sulfate proteoglycans. J Biol Chem. 2013;288(1):510–519.
   PubMed Web of Science ®Google Scholar
• Jansen S, Perrakis A, Ulens C, et al. Structure of NPP1, an ectonucleotidepyrophosphatase/phosphodiesterase involved in tissue calcifi cation. Structure. 2012;20(11):1948–1959.
   PubMed Web of Science ®Google Scholar
• Albers HMHG, Ovaa H. Chemical evolution of autotaxin inhibitors. Chem Rev. 2012;112(5):2593–2603.
   PubMed Web of Science ®Google Scholar
• Benesch MG, Ko YM, Mcmullen TP, et al. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 2014;588(16):2712–2727.
   PubMed Web of Science ®Google Scholar
• Jansen S, Stefan C, Creemers JW, et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis‐enhancing lysophospholipase D. J Cell Sci. 2005;118(14):3081–3089.
   PubMed Web of Science ®Google Scholar
• Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. 2014;55(6):1010–1018.
   PubMed Web of Science ®Google Scholar
• Giganti A, Rodriguez M, Fould B, et al. Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem. 2008;283(12):7777–7789.
   Web of Science ®Google Scholar
• Van Meeteren LA, Moolenaar WH. Regulation and biological act-ivities of the autotaxin-LPA axis. Prog Lipid Res. 2007;46(2):145–160.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Okudaira S, Igarashi K, et al. Identification and biochemical characterization of a novel autotaxin isoform, ATXdelta, with a four-amino acid deletion. J Biochem. 2012;151(1):89–97.
   PubMed Web of Science ®Google Scholar
• Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie. 2010;92(6):698–706.
   PubMed Web of Science ®Google Scholar
• Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010;91(3–4):130‐138.
   PubMed Web of Science ®Google Scholar
• Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277(50):48737–48744.
   PubMed Web of Science ®Google Scholar
• Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158(2):227–233.
   PubMed Web of Science ®Google Scholar
• Castagna D, Budd DC, Macdonald SJF, et al. Development of autotaxin inhibitors: an overview of the patent and primary literature. J Med Chem. 2016;59(12):5604–5621.
   PubMed Web of Science ®Google Scholar
• Chun J, Hla T, Lynch KR, et al. Lysophospholipid Receptor Nomenclature. Pharmacol Rev. 2010;62(4):579–587.
   PubMed Web of Science ®Google Scholar
• Yanagida K, Kurikawa Y, Shimizu T, et al. Current progress in non-Edg family LPA receptor research. Biochim Biophys Acta. 2013;1831(1):33–41.
   PubMed Web of Science ®Google Scholar
• Hordijk PL, Verlaan I, van Corven EJ, et al. Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway.. J Biol Chem. 1994;269(1):645–651.
   PubMed Web of Science ®Google Scholar
• Kumagai N, Morii N, Fujisawa K, et al. ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation. J Biol Chem. 1993;268(33):24535–24538.
   PubMed Web of Science ®Google Scholar
• Jonathan Z, Astrid E, Krueger B. Vectorial secretion of CTGF as a cell-type specific response to LPA and TGF-β in human tubular epithelial cells. Cell Commun Signal. 2012;10(1):25–39.
   PubMedGoogle Scholar
• Van Corven EJ, Groenink A, Jalink K, et al. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell. 1989;59(1):45–54.
   PubMed Web of Science ®Google Scholar
• Xianjun F, Shuangxing Y, Ruth L, et al. Lysophosphatidic acid prevents apoptosis in fibroblasts via Gi-protein-mediated activation of mitogen-activated protein kinase. Biochem J. 2000;352(1):135–143.
   PubMedGoogle Scholar
• Kranenburg O, Moolenaar WH. Ras-MAP kinase signalling by lysophosphatidic acid and other G protein coupled receptor agonists. Oncogene. 2001;20(13):1540–1546.
   PubMed Web of Science ®Google Scholar
• Takeda H, Matozaki T, Takada T, et al. Pi 3-kinase gamma and protein kinase C-zeta mediate RAS-independent activation of MAP kinase by a Gi </sub> protein-coupled receptor. Embo J. 1999;18(2):386–395.
   PubMed Web of Science ®Google Scholar
• Kranenburg O, Poland M, van Horck FPG, et al. Activation of RhoA by lysophosphatidic acid and G12/13 subunits in neuronal cells: induction of neurite retraction. Mol Biol Cell. 1999;10(6):1851–1857.
   PubMed Web of Science ®Google Scholar
• Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3(8):582–591.
   PubMed Web of Science ®Google Scholar
• Nishimasu H, Okudaira S, Hama K, et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol. 2011;18(2):205–212.
   PubMed Web of Science ®Google Scholar
• Nishimasu H, Ishitani R, Aoki J, et al. A 3D view of autotaxin. Trends Pharmacol Sci. 2012;33(3):138–145.
   PubMed Web of Science ®Google Scholar
• Joncour A, Desroy N, Housseman C, et al. Discovery, structure-activity relationship, and binding mode of an imidazo[1,2a]pyridine series of autotaxin inhibitors. J Med Chem. 2017;60(17):7371–7392.
   PubMed Web of Science ®Google Scholar
• Salgado-Polo F, Perrakis A. The structural binding mode of the four autotaxin inhibitor types that differentially affect catalytic and non-catalytic functions. Cancers (Basel). 2019;11(10):1577–1594.
   Web of Science ®Google Scholar
• Gierse J, Thorarensen A, Beltey K, et al. A novel autotaxin inhibitor reduced lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther. 2010;2(1):310–317.
   Google Scholar
• Jones SB, Pfeifer LA, Bleisch TJ, et al. Novel autotaxin inhibitors for the treatment of osteoarthritis pain: lead optimization via structure-based drug design. ACS Med Chem Lett. 2016;7(9):857–861.
   PubMed Web of Science ®Google Scholar
• Keune WJ, Potjewyd F, Heidebrecht T, et al. Rational design of Autotaxin inhibitors by structural evolution of endogenous modulators. J Med Chem. 2017;60(5):2006‐2017.
   Web of Science ®Google Scholar
• Stein AJ, Bain G, Prodanovich P, et al. Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding. Mol Pharmacol. 2015;88(6):982‐992.
   PubMed Web of Science ®Google Scholar
• Bain G, Shannon KE, Huang F, et al. Selective inhibition of autotaxin is efficacious in mouse models of liver fibrosis. J Pharmacol Exp Ther. 2017;360(1):1–13.
   PubMed Web of Science ®Google Scholar
• Matralis AN, Afantitis A, Aidinis V. Development and therapeutic potential of autotaxin small molecule inhibitors: from bench to advanced clinical trials. Med Res Rev. 2019;39(3):976–1013.
   PubMed Web of Science ®Google Scholar
• Black KE, Berdyshev E, Bain G, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. Faseb J. 2016;30(6):2435–2450.
   PubMed Web of Science ®Google Scholar
• Galapagos. Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. WO2014139882 (2014).
   Google Scholar
• Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol. 2011;12(10):674–679.
   PubMed Web of Science ®Google Scholar
• Tabchy A, Tigyi G, Mills GB. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. Nat Struct Mol Biol. 2011;18(2):117–118.
   PubMed Web of Science ®Google Scholar
• Keune WJ, Hausmann J, Bolier R, et al. Steroid binding to autotaxin links bile salts and lysophosphatidic acid signalling. Nat Commun. 2016;7(1):11248.
   PubMedGoogle Scholar
• Desroy N, Housseman C, Bock X, et al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin1-yl]-8-methyli midazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a first-in-class autotaxin inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2017;60(9):3580–3590.
   PubMed Web of Science ®Google Scholar
• Shenyang Pharmaceutical University. Imidazo[1,2-a]pyridine derivatives and methods of preparing and using thereof. CN111187262 (2020).
   Google Scholar
• Guangzhou Henovcom Bioscience. ATX inhibitors, preparation method thereof and application thereof. WO2019029620 (2019).
   Google Scholar
• Cancer Research Technology Limited. Autotaxin inhibitory compounds. WO 2016124939 (2016).
   Google Scholar
• Shah P, Cheasty A, Foxton C, et al. Discovery of potent inhibitors of the lysophospholipase autotaxin. Bioorg Med Chem Lett. 2016;26(22):5403–5410.
   PubMed Web of Science ®Google Scholar
• Fronthera US, Pharmaceuticals LLC Autotaxin inhibitors and uses thereof. WO2019228403 (2019).
   Google Scholar
• Suzhou Sinovent Pharmaceuticals. Heterocyclic compounds, application thereof and pharmaceutic composition comprising same. WO2019158107 (2019).
   Google Scholar
• Shenyang Pharmaceutical University. Indol-based ATX inhibitors and methods of preparing and using thereof. CN111187261 (2020).
   Google Scholar
• Lei HR, Guo M, Li XP, et al. Discovery of novel indole-based allosteric highly potent ATX inhibitors with great in vivo efficacy in a mouse lung fibrosis model. J Med Chem. 2020;63(13):7326–7346.
   PubMed Web of Science ®Google Scholar
• Pharmakea Inc. Heterocyclic autotaxin inhibitor compounds. WO2016144704 (2016).
   Google Scholar
• Shanxi Institute of Biology. Carbazole compounds as autotaxin inhibitors and preparation method thereof and uses thereof. CN107266356 (2017).
   Google Scholar
• Roche H-L. New bicyclic compounds as ATX inhibitors. WO2018167113 (2018).
   Google Scholar
• Hoffmann-La Roche. Bicyclic compounds as ATX inhibitors. WO2017050792 (2017).
   Google Scholar
• Hoffmann-La Roche. Bicyclic compounds as ATX inhibitors. WO2017050732 (2017).<.collab>
   Google Scholar
• Roche H-L. New bicyclic compounds as dual ATX/CA inhibitors. WO2017050747 (2017).
   Google Scholar
• Hoffmann-La Roche. New bicyclic compounds as dual ATX/CA inhibitors. WO2017050791 (2017).<.collab>
   Google Scholar
• Guangzhou Henovcom Bioscience. Azaspiro compound and preparation method thereof and use thereof. WO2018153312 (2018).
   Google Scholar
• Guangzhou Henovcom Bioscience. Aromatic heterocyclic compound, and pharmaceutical composition and use thereof. WO2019223721 (2019).
   Google Scholar
• Legochem Biosciences. Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same. WO2018212534 (2018).
   Google Scholar
• Roche H-L. Heterocyclic inhibitors of ATX. WO2020119896 (2020).
   Google Scholar
• Jing TF, Miao XQ, Jiang F, et al. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors. Bioorg Med Chem. 2018;26(8):1784‐1796.
   Web of Science ®Google Scholar
• Shenyang Pharmaceutical University. Tetrahydropyrido[4,3-d]pyrimidine derivatives and use thereof. CN108586454 (2018).
   Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Novel 2-amino-pyridine and 2-aminopyrimidine derivatives and medicinal use thereof. WO2015163435A1 (2015).
   Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Novel 3,5-disubstituted pyridine and 3,5-disubstituted pyridazine derivatives and pharmaceutical use of same. WO2020022470 (2020).
   Google Scholar
• Inhibitaxin Limited. Substituted pyridazines for the treatment of pain. US9273011 (2016).
   Google Scholar
• Boehringer Ingelheim International GmbH. Novel pyridazines. US20200131151 (2020).
   Google Scholar
• Kuttruff CA, Ferrara M, Bretschneider T, et al. Discovery of BI-2545: A novel autotaxin inhibitor that significantly reduces LPA levels in vivo. ACS Med Chem Lett. 2017;8(12):1252–1257.
   PubMed Web of Science ®Google Scholar
• The University of Tokyo, Tohoku University and Shionogi & CO. Fused 9-membered ring derivatives having autotaxin inhibitory activity. JP2016193887 (2016).
   Google Scholar
• Shionogi & Co. 5-Carbonylaminoalkyl-substituted fused pyrazole derivative having autotaxin inhibitory activity. WO2017033966 (2017).
   Google Scholar
• Shionogi & Co. Condensed pyrazole derivative unsubstituted at 7-position with inhibitory activity on autotaxin. JP2016164154 (2016)
   Google Scholar
• Shionogi & Co. 2-Position unsubstituted pyrimidinone derivative having autotaxin inhibitory activity. JP2017014134 (2017).
   Google Scholar
• Shionogi & Co. Condensed-ring pyrimidinone derivative having autotaxin inhibitory activity. JP2017149693 (2017).
   Google Scholar
• Roche H-L. Bicyclic quinazolinone derivatives. WO2016162390 (2016).
   Google Scholar
• University of Tennessee Research Foundation. Autotaxin inhibitors. WO2017210527 (2017).
   Google Scholar
• Fells JI, Lee SC, Fujiwara Y, et al. Hits of a high‐throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. Mol Pharmacol. 2013;84(3):415‐424.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Norman DD, Lee SC, et al. Highly potent non‐carboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells. J Med Chem. 2017;60(4):1309‐1324.
   Web of Science ®Google Scholar
• Fells JI, Lee SC, Norman DD, et al. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif. Febs J. 2014;281(4):1017‐1028.
   PubMed Web of Science ®Google Scholar
• Roche H-L. Heterocyclic compounds useful as dual ATX/CA inhibitors. WO2018167001 (2018).
   Google Scholar
• Novartis AG Autotaxin inhibitors. US20170007614 (2017).
   Google Scholar
• Hoffmann La R Phenoxymethyl derivatives. WO2017037146 (2017).
   Google Scholar
• National and Kapodistrian University of Athens. Autotaxin inhibitors and uses thereof. WO2016184561 (2016).
   Google Scholar
• Ferry G, Moulharat N, Pradere JP, et al. S32826, A nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther. 2008;327(3):809–819.
   PubMed Web of Science ®Google Scholar
• Jiang G, Madan D, Prestwich GD. Aromatic phosphonates inhibit the lysophospholipase activity of autotaxin. Bioorg Med Chem Lett. 2011;21(17):5098–5101.
   PubMed Web of Science ®Google Scholar
• Nikolaou A, Ninou I, Kokotou MG, et al. Hydroxamic acids constitute a novel class of Autotaxin inhibitors that exhibit in vivo efficacy in a pulmonary fibrosis model. J Med Chem. 2018;61(8):3697–3711.
   PubMed Web of Science ®Google Scholar
• Cancer Research Technology Limited. Autotaxin inhibitors. WO2016124938 (2016).
   Google Scholar
• Jiangxi Academy of Medical Sciences. An anti-fibrotic compound and pharmaceutical composition and use thereof. CN110627774 (2019).
   Google Scholar
• Taiwanj Pharmaceuticals. Benzene fused heterocyclic compound and use thereof. WO2019108943 (2019).
   Google Scholar
• Taiwanj Pharmaceuticals. Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same. WO2019051222 (2019).
   Google Scholar
• Zulfikar S, Mulholland S, Adamali H, et al. Inhibitors of the autotaxin-lysophosphatidic acid axis and their potential in the treatment of interstitial lung disease: current perspectives. Clin Pharmacol. 2020;12:97–108.
   PubMed Web of Science ®Google Scholar